The performance of companies tied to flagship drugs like Viagra presents a challenging investment picture. While the initial rise of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the expiry in key markets has introduced substantial volatility. Investors are now facing the consequences of generic competition